The field of gastroenterology is evolving rapidly due to advances in science and technology, as well as important developments in drug discovery and precision medicine. Fatty liver disease is an emerging epidemic that effects 80 million Americans and will soon be the most common cause for liver failure and the leading indication for liver transplantation. Precision medicine advancements in blood-based cancer biomarkers have created an important opportunity for our partners to participate in premier research – thus advancing critical new diagnostics that will enhance patient acceptance and access to screening. Our research programs create the opportunity for our partnered physicians to participate in this groundbreaking work and offer this care option to their patients most in need.
With the growing need for high-quality community research programs, we are also embracing advancements that bring emerging science to patients in the clinical setting. Indications include luminal GI conditions, such as inflammatory bowel disease, irritable bowel syndrome, celiac disease, and microbiome and eosinophilic disorders.
Condition We’re Focused On
NASH: The Silent Killer That Has Everyone Talking
Nonalcoholic steatohepatitis (NASH) is a silent chronic disease that remains asymptomatic until the complications of liver cirrhosis are manifested. Patients are often diagnosed only when they develop signs of advanced liver disease.
Between 80 and 100 million Americans have nonalcoholic fatty liver disease (NAFLD), while tens of millions of people suffer from NASH.
The Problem That’s Only Getting Worse
Certain risk factors, such as diabetes, hypertension, and obesity, identify those patients who should undergo additional NASH screening and evaluation. The ObjectiveHealth platform provides technologies that accelerate the diagnosis of this condition.
Between 80 and 100 million Americans have nonalcoholic fatty liver disease (NAFLD), while tens of millions of people suffer from NASH. In a large percentage of those affected, scarring (fibrosis) can develop in the liver. Many will develop the advanced form of NASH, which can eventually lead to cirrhosis and liver failure.
In the coming years, NASH will be the leading indication for liver transplantation. In addition to liver failure, NASH patients also face a dramatically increased risk for liver cancer. The NASH epidemic is already causing a huge economic strain, and it is only getting worse. Today, we’re spending $5 billion annually in healthcare costs related to the disease. By 2030, this could rise to $30 billion.
A Look at the NASH Numbers
The number of people in the US who have NASH.
The amount the US spends annually in healthcare costs related to NASH.
The year when NASH became the leading indication for liver transplantation in the US.
Easing the Burden
While we work through clinical trials in pursuit of initial therapies, our NASH research platform creates more regular, face-to-face patient care and monitoring. This increases patient engagement, identifies disease progression early, and improves health outcomes.
We promote lifestyle and diet changes that can have an immediate positive impact once a patient is diagnosed. Through our research partnerships, we are playing a major role in discovering the first available treatments for those eagerly anticipating new therapeutic discoveries.